Absolute oral bioavailability and possible metabolic pathway of panduratin A from Boesenbergia rotunda extract in beagle dogs
Issued Date
2023-01-01
Resource Type
ISSN
13880209
eISSN
17445116
Scopus ID
2-s2.0-85151189732
Pubmed ID
36994846
Journal Title
Pharmaceutical Biology
Volume
61
Issue
1
Start Page
590
End Page
597
Rights Holder(s)
SCOPUS
Bibliographic Citation
Pharmaceutical Biology Vol.61 No.1 (2023) , 590-597
Suggested Citation
Boonyarattanasoonthorn T., Kongratanapasert T., Jiso A., Techapichetvanich P., Nuengchamnong N., Supannapan K., Kijtawornrat A., Khemawoot P. Absolute oral bioavailability and possible metabolic pathway of panduratin A from Boesenbergia rotunda extract in beagle dogs. Pharmaceutical Biology Vol.61 No.1 (2023) , 590-597. 597. doi:10.1080/13880209.2023.2190777 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/82319
Title
Absolute oral bioavailability and possible metabolic pathway of panduratin A from Boesenbergia rotunda extract in beagle dogs
Other Contributor(s)
Abstract
Context: Attempts are ongoing to develop medications to fight against the COVID-19 pandemic. Our previous study revealed the in vitro anti-SARS-CoV-2 activity of fingerroot [Boesenbergia rotunda (L.) Mansf. (Zingiberaceae)] and its phytochemical, panduratin A. Objective: To investigate the pharmacokinetic profiles of panduratin A as a pure compound and in a fingerroot extract formulation in beagle dogs. Materials and methods: A total of 12 healthy dogs were randomly divided into three groups, a single dose of 1 mg/kg panduratin A by intravenous and multiple doses of 5 and 10 mg/kg panduratin A fingerroot extract formulation by oral administration for seven consecutive days. The plasma concentration of panduratin A was determined by LCMS. Results: The peak concentrations of a single dose of 5 and 10 mg/kg panduratin A fingerroot extract formulation were 12,416 ± 2,326 and 26,319 ± 8,221 µg/L, respectively. Increasing the oral dose of fingerroot extract formulation, equivalent to panduratin A 5–10 mg/kg, showed dose proportionality, with an approximately 2-fold increase in C max and AUC. The absolute oral bioavailability of panduratin A in the fingerroot extract formulation was approximately 7–9%. The majority of panduratin A was biotransformed into several products via oxidation and glucuronidation, and predominantly excreted via the faecal route. Conclusion: The oral formulation of fingerroot extract was safe in beagle dogs, and increasing dose showed dose proportionality in terms of the systemic exposure of panduratin A. This information will support the phytopharmaceutical product development of fingerroot extract against the COVID-19 pandemic.
